The Patent Finder
GI

GlaxoSmithKline Intellectual Property Development Limited

First filing 2007
OverviewNotableFeesChangesFamiliesPatent listSources & methods

124 patents currently held

40 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Apr 2027. from the record

Of the 40 now held by other companies, 9 were conveyed to Galvani Bioelectronics Limited in the filing they arrived in, and 31 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Apr 2027
Next term end
89
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 21, 2026
    The maintenance fee for Heterocyclic Amides as Kinase Inhibitors (US 10,292,987) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
  • 2 fees due Dec 6 to 25, 2026 · next Dec 6
  • 4 fees due Jan 9 to 30, 2027 · next Jan 9
  • 1 fee due Mar 10, 2027
    The maintenance fee for Benzoimidazole Derivatives as PAD4 Inhibitors (US 10,407,407) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
  • 8 fees due Apr 1 to 30, 2027 · next Apr 1
  • 3 fees due May 12 to 28, 2027 · next May 12
  • 1 fee due Jul 16, 2027
    The maintenance fee for Compounds Useful in HIV Therapy (US 11,873,310) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
  • 4 fees due Sep 10 to 30, 2027 · next Sep 10
  • 3 fees due Oct 2 to 30, 2027 · next Oct 2
  • 3 fees due Nov 5 to 7, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 19, 2026
  • 2 terms have ended since Aug 19, 2026

What they patent

The 5 largest of its 89 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US D679,586Lid/Tray Package for an Inhalation Device
In force
 · High confidence
In forceHigh confidence
US 8,962,825Hydroxamates as Inhibitors of Histone Deacetylase
In force
 · High confidence
In forceHigh confidence
US 7,973,181Hydroxamic Acid Derivatives as Inhibitors of Hdac Enzymatic Activity
In force
 · Medium confidence
In forceMedium confidence
US D754,533Tray Package For an Inhalation Device
In force
 · High confidence
In forceHigh confidence
US 9,624,261Buffer System for Protein Purification
In force
 · High confidence
In forceHigh confidence
US 9,868,761Buffer System for Protein Purification
In force
 · High confidence
In forceHigh confidence
US 10,730,862Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
In force
 · High confidence
In forceHigh confidence
US 9,763,965Aggregate Particles
In force
 · High confidence
In forceHigh confidence
US 9,556,152Heterocyclic Amides as Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,624,202Heterocyclic Amides as Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 124 patents shown.
Pro members see all 124.
Pro members: see all 124 patents
Also on record, not counted in the 124: 40 patents in force now held by others · 111 patents ended · 81 applications pending · 195 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited